Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis

Guan, Ruifang; Yang, Qing; Yang, Xiaolei; Du, Wandi; Li, Xuening; Ma, Guoyi

doi:10.3389/fphar.2022.998816

Cited by 15 publications

(19 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, tirzepatide were more effective than other drugs in reducing bodyweight of 5%, 10%, or 15%. More importantly, compared with placebo, GLP-1 RAs and insulin, tirzepatide can significantly reduce their HbA1c level of patients, and the results were same with other studies [ 32 , 38 ].…”

Section: Discussionsupporting

confidence: 82%

Weight loss efficiency and safety of tirzepatide: A Systematic review

Lin

Ling

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Objective Tirzeptide is a novel glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drug, which shows good efficiency for weight loss. Therefore, we aim to investigate the efficacy and safety of tirzepatide for weight loss in type 2 diabetes mellitus (T2DM) and obesity patients in this meta-analysis study. Methods Cochrane Library, PubMed, Embase, Clinical Trials, and Web of Science were searched from inception to October 5, 2022. All randomized controlled trials (RCTs) were included. The odds ratio (OR) was calculated using fixed-effects or random-effects models by Review Manager 5.3 software. Results In total, ten studies (12 reports) involving 9,873 patients were identified. A significant loss body weight in the tirzepatide group versus the placebo by -9.81 kg (95% CI (-12.09, -7.52), GLP-1 RAs by -1.05 kg (95% CI (-1.48, -0.63), and insulin by -1.93 kg (95% CI (-2.81, -1.05), respectively. In sub-analysis, the body weight of patients was significantly reduced in three tirzepatide doses (5 mg, 10 mg, and 15 mg) when compared with those of the placebo/GLP-1 RA/insulin. In terms of safety, the incidence of any adverse events and adverse events leading to study drug discontinuation was higher in the tirzepatide group, but the incidence of serious adverse events and hypoglycaemia was lower. Additionally, the gastrointestinal adverse events (including diarrhea, nausea, vomiting and decreased appetite) of tirzepatide were higher than those of placebo/basal insulin, but similar to GLP-1 RAs. Conclusion In conclusion, tirzeptide can significantly reduce the weight of T2DM and patient with obesity, and it is a potential therapeutic regimen for weight-loss, but we need to be vigilant about its gastrointestinal reaction.

show abstract

Section: Discussionsupporting

confidence: 82%

Weight loss efficiency and safety of tirzepatide: A Systematic review

Lin

Ling

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…As reported by previous network meta analysis, tirzepatide administered at all doses demonstrated higher weight loss effectiveness in comparison with with glargine, degludec. When compared with GLP-1RA, a statistically signi cant reduction in body weight was observed with 10mg and 15 mg of tirzepatide, among that, 15 mg of tirzepatide has the best effection reducing body weight (SUCRA probability: 99.7%) [43] . This is similar to our ndings, suggesting that tirzepatide has a clear advantage in weight loss with T2DM, especially 15mg of tirzepatide.…”

Section: Discussionmentioning

confidence: 93%

Efficacy and safety of different doses of tirzepatide in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis

Zhu,

Huang,

Luo

et al. 2024

Preprint

View full text Add to dashboard Cite

Introduction: This study aims to evaluate the effectiveness and safety of different doses of tirzepatide on hypoglycemic, weight-loss, improvement of beta-cell function and insulin resistance in patients with type 2 diabetes mellitus compared with other glucose-lowering drugs or placebo. Research Design and Methods: Searches were conducted for PubMed, Cochrane Library, Web of Science and Embase for randomized controlled trials (RCTs) of tirzepatide from their inception to 2023. The network meta-analysis followed the PRISMA guidelines. Based on the Cochrane risk of bias tool, we analyzed the included RCTs using Stata 15.1. The standardized mean difference and surface under the cumulative ranking curve were presented for each result. An evaluation of publication bias was conducted using funnel plots. Results: Data from 17 studies involving 10405 patients was analyzed. Tirzepatide 10 mg and 15 mg were more effective at hypoglycemic control and weight loss than basal insulin (glargine or degludec) or GLP-1RAs (dulaglutide or semaglutide). Tirzepatide 15mg plays a leading role in lowering body weight (SCURA probability: 98.3%), fasting insulin (95.4%), fasting C-Peptide (91.8%), fasting blood glucose (88.2%) and glycated hemoglobin (85.7%). As for safety, 7407 (72%) had at least one treatment-emergent adverse events and most of that were gastrointestinal adverse events. Conclusions: Tirzepatide 15 mg, not only exhibited a favorable hypoglycemic and weight-loss efficacy, but also achieve a reduction of fasting insulin and fasting C-Peptide by comparison with insulin and GLP1-RAs. It is need of more well-designed RCTs to evaluate potential benefits on insulin resistance and pancreatic beta cell function of tirzepatide.

show abstract

“…Tirzepatide, at all doses, has been shown to have a similar safety profile relative to GLP-1 receptor agonists. However, there is a dose-dependent increase in GI adverse events, compared to placebo, with nausea and vomiting being one of the more prominent side effects [16,81]. Although these adverse effects may not be severe, they remain a cause of concern because GI side effects are common causes of discontinuation of T2DM medications [16,82].…”

Section: Glp-1 Receptor Agonists Versus Tirzepatidementioning

confidence: 99%

Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis

Pan,

Tan,

Chin

et al. 2024

Obesity

View full text Add to dashboard Cite

ObjectiveThis network meta‐analysis evaluates the efficacy and safety of tirzepatide compared to glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and other weight loss drugs in the treatment of overweight and obesity.MethodsMEDLINE, Embase, and Cochrane CENTRAL were searched for randomized controlled trials on tirzepatide, GLP‐1 RA, and weight loss drugs approved by the US Food and Drug Administration. A network meta‐analysis was performed, drawing direct and indirect comparisons between treatment groups. Network diagrams and surface under the cumulative ranking curve analysis were performed for primary (≥5%, ≥10%, ≥15%, absolute weight loss) and secondary outcomes and adverse effects.ResultsThirty‐one randomized controlled trials, involving more than 35,000 patients, were included in this study. Tirzepatide 15 mg ranked in the top three across weight‐related parameters, glycemic profile (glycated hemoglobin), lipid parameters (total cholesterol, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, triglycerides), and blood pressure. Tirzepatide 15 mg had the highest efficacy compared with placebo for achieving ≥15% weight loss (risk ratio 10.24, 95% CI: 6.42–16.34). As compared to placebo, tirzepatide and GLP‐1 RA across all doses had significant increases in gastrointestinal adverse effects.ConclusionsThe superiority of tirzepatide and GLP‐1 RA in inducing weight loss and their ability to target multiple metabolic parameters render them promising candidates in the treatment of patients with overweight and obesity.

show abstract

Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis

Cited by 15 publications

References 39 publications

Weight loss efficiency and safety of tirzepatide: A Systematic review

Weight loss efficiency and safety of tirzepatide: A Systematic review

Efficacy and safety of different doses of tirzepatide in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis

Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis

Contact Info

Product

Resources

About